Agenda - Thursday 18th September - Main Conference Day Three

Showing 1 of 1 Streams

Development of Emerging Cell & Gene Therapies

8:50am - 9:00am

Chairperson’s Opening Remarks: Development of Emerging Cell & Gene Therapies

Nathan Yozwiak - Head of Research, Gene and Cell Therapy Institute, Mass General Brigham

9:00am - 9:30am

Starting with the End in Mind: Designing Smart for Successful Cell & Gene Therapy Development

Francesca Vitelli, PhD - VP Global head of Process and Analytical Development and Innovation (PADI), Minaris
Brian Laskowski - VP, Head of Quality Assurance CMC, Beacon Therapeutics
Sam Cooper - VP, Cell and Gene Logistics, Cardinal Health
Pratima Cherukuri - General Manager and Senior Vice President for the Plasmid Business, Bionova Scientific

9:30am - 10:00am

Development of Next-Gen Cell & Gene Therapies - Gamma-Delta T Cell Engager Technology Case Study

Kate Rochlin - Chief Operating Officer, IN8bio

10:00am - 10:30am

Manufacturing of LNPs, from pDNA and mRNA to LNP with Multiple Nucleic Acids Payloads

Aleš Strancar, PhD - Managing Director, Sartorius BIA Separations

Showing 1 of 1 Streams

Development of Emerging Cell & Gene Therapies

11:15am - 11:45am

Discovery and Development of Next Generation TCR-T Cell Therapies Against Mutant KRAS for the Treatment of Advanced Pancreatic Cancer

Hugh Salter - Chief Scientific Officer, Anocca AB

11:45am - 12:15pm

Stromal-Free, GMP-Compatible Bioprocess for Generating Allogeneic CAR-γδ T Cells from Cord Blood CD34+ HSPC

Victor Manuel Diaz Cortes - Research Director, OneChain Immunotherapeutics S.L.

12:15pm - 12:30pm

Gene Therapy for Immune Reprogramming and the Treatment of Inflammatory Diseases

Shahrooz Rabizadeh - CEO & Co-Founder, Sagittarius Bio

Showing 1 of 1 Streams

Development of Emerging Cell & Gene Therapies

1:55pm - 2:00pm

Chairperson's Opening Remarks

Nathan Yozwiak - Head of Research, Gene and Cell Therapy Institute, Mass General Brigham

2:00pm - 2:15pm

Small Molecule-Controlled Genetic Neuromodulation: Combining the Tunability of Pharmacotherapy and Precision of Gene Therapy

Tamás Kitka - Founder, Managing Director, CREATe Therapeutics

2:15pm - 2:30pm

Development of an Expandable and Functional Hepatocyte Cell Therapy

Marcus Lehmann - Associate Director, Drug Product Process Development, Satellite Bio

2:35pm - 3:05pm

CGT Keynote Plenary: Panel Discussion: Harnessing AI & Digitalization for Cell and Gene Therapy Manufacturing – Unlocking Efficiency, Control and Scalability

Kat Kozyrytska - Consultant, AI Implementation & Tech Commercialization
Jared Auclair, PhD - Dean College of Professional Studies and Director of Bioinnovation, College of Science at Northeastern University
Aaron Edwards - CEO + Co-Founder, KiraGen Bio
Igor Gonzalez - Digital CMC Scientist - In Silico First Program, Takeda
Mark Duerkop - Chief Executive Officer, Novasign, Austria

3:05pm - 3:35pm

Drug Development Reinvented: Precision Strategies to Rapidly Deliver Transformative Therapies for Patients

Helen Sabzevari, PhD - President and CEO, Precigen

Thursday 18th September - Main Conference Day ThreeThursday, 18 September 2025 - ET (Eastern Time, GMT-05:00)

Get the Latest Event Updates